Press coverage about Bellerophon Therapeutics (NASDAQ:BLPH) has been trending somewhat positive recently, Accern Sentiment reports. The research group ranks the sentiment of news coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Bellerophon Therapeutics earned a media sentiment score of 0.10 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 46.1278390074668 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

Here are some of the news stories that may have impacted Accern Sentiment Analysis’s rankings:

Shares of Bellerophon Therapeutics (NASDAQ:BLPH) traded up $0.12 during mid-day trading on Tuesday, hitting $1.50. The stock had a trading volume of 380,500 shares, compared to its average volume of 745,930. Bellerophon Therapeutics has a one year low of $0.43 and a one year high of $1.98.

Several analysts have weighed in on BLPH shares. Zacks Investment Research cut Bellerophon Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, August 11th. HC Wainwright reaffirmed a “buy” rating and issued a $5.00 price target on shares of Bellerophon Therapeutics in a research note on Wednesday, September 6th. Finally, ValuEngine raised Bellerophon Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Friday, September 8th.

TRADEMARK VIOLATION NOTICE: This news story was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another site, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be accessed at

Bellerophon Therapeutics Company Profile

Bellerophon Therapeutics, Inc is a clinical-stage therapeutics company. The Company is focused on developing products at the intersection of drugs and devices that address medical needs in the treatment of cardiopulmonary diseases. The Company is focused on the development of its nitric oxide therapy for patients with pulmonary hypertension (PH), using its delivery system, INOpulse, with pulmonary arterial hypertension (PAH) as the lead indication.

Insider Buying and Selling by Quarter for Bellerophon Therapeutics (NASDAQ:BLPH)

Receive News & Stock Ratings for Bellerophon Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics Inc. and related stocks with our FREE daily email newsletter.